| Professional Training |
 |
| 1992 - 1995 |
Fellow in the Hematology/Oncology
Emory University, Atlanta, Georgia
Basic Research - Platelet Physiology
Milwaukee Blood Center |
February 1989 -
June 1989 |
Externship of Internal Medicine
Lutheran Medical Center, Cleveland, Ohio |
| 1985 - 1986 |
Internship
University Hospital Tirsheen University
School of
Medicine,
Latakia, Syria |
| September 1985 |
Rotation in Internal Medicine
Southmead General Hospital, Bristol
School of Medicine, Bristol, England |
| August 1985 |
Rotation Obstetric/Gynecology
Southmead General Hospital, Bristol
School of Medicine, Bristol, England |
| July - September 1984 |
Three month Rotation in Internal Medicine
Northern General Hospital
Sheffield School of Medicine,
Sheffield, England |
|
| Faculty Appointments |
| |
Beaufort Memorial Hospital, South Carolina
Active staff member |
| July 1, 2008 |
A.T. Still University, Arizona
Consulting Associate, Department of Medicine |
| 2006 |
Duke University
Medical Center
Consulting Associate, Department of Medicine |
|
| Other Appointments |
| |
Medical DIrector, Sea Island Cancer Center
Port Royal, South Carolina |
| |
Chairman, Department of Oncology,
Beaufort Memorial Hospital
Beaufort, South Carolina |
| |
Cancer Program Medical Director, Beaufort Memorial Hospital
Beaufort, South Carolina |
| 2001 - 2007 |
Vice Chief of Staff, Beaufort Memorial Hospital
Beaufort, South Carolina |
| 1999 - 2001 |
Chairman, Department of Internal Medicine, Beaufort Memorial Hospital
Beaufort, South Carolina |
|
| Education |
| 1986 |
Tisbreen University, School of Medicine, Latakia, Syria
Doctor of Medicine, December 1986 |
|
| Societies |
| |
American Medical Association |
| |
American Cancer Society |
| |
South Carolina Medical Association |
| |
South Carolina Oncology Society |
| |
American Society of Clinical Oncology |
| |
American Society of Hematology |
| |
Association of Community Cancer Centers |
| |
National Arab American Medical Association |
|
| State Licenses |
| |
South Carolina, 1995 - present, Internal Medicine & Oncology |
| |
Georgia, 1992 - present |
|
| Chapters in Books |
Co- Author of the Chapter, Biologic Response Modifiers
The Chemotherapy Sourcebook, Second Edition 1986,
William's & Wilken's |
|
| Specific Clinical Research Protocols |
| Roche sponsored XELODA-A-DVS-ML 18491 |
| Roche sponsored Xeloda/Avastin Met Breast - ML 18527 |
| Sigma Tau Fatigue in Breast Cancer - ST03-103 |
Participated as Principal Investigator at Beaufort Memorial Hospital
in the following clinical trials:
- Pacct/Tailorx - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for
Treatment: The TAILORx Trial
- SWOG 307- Bisphosphonates as Adjuvant Treatment in Breast Cancer
- CALGB 369901 - Chemotherapy Decisions and Outcomes in
Women age 65 or Older With Operable, Newly Diagnosed Breast Cancer
- ECOG 5202- A Randomized Phase III Study Comparing 5-FU
Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin
and Bevacizumab in Patients with Stage II Colon Cancer at High
Risk for Recurrence to Determine Prospectively the Prognostic
Value of Molecular Markers
- ECOG 5204 - A Clinical Trial Comparing Preoperative Radiation
Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous
Infusion of S-Fluorouracil with or without Oxaliplatin in the
Treatment of Patients With Operable Carcinoma of the Rectum
- CALGB 80405 - Trial of Irinotecan/5-FU/Leucovorin or
Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab
(C225), or with the Combination of Bevacizumab and
Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
- NSABP R04 - Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy
and Continuous Intravenous Infusion of 5-Fluorouracil with or
without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum
- CALGB 40502 - A Randomized Phase III Trial of Weekly
Paclitaxel Compared to Weekly Nanoparticle Albumin Bound
Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as
First-Line Therapy for Locally Recurrent or Metastatic Breast
Cancer
|
|
| Community Activities |
| Relay for Life |
| Community Education through the American Cancer Society |
